Business Description This Report provides a comprehensive Sales & Margin summary analysis for Valentis, Inc. Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.
Valentis, Inc.. The Group's principal activity is to develop products for peripheral arterial disease and is a clinical-stage biotechnology company. The Group focuses on research, preclinical and early stage clinical development of products in several therapeutic areas including cardiovascular disorders, oncology, haematology and immunology. The Group has three product platforms for the development of novel therapeutics namely the gene medicine, GeneSwitch (r) and DNA vaccine platforms. The Gene medicine platform includes a comprehensive array of proprietary nucleic acid delivery systems. GeneSwitch (r) platform controls erythropoietin protein production from an injected gene by orally administered drug. Synthetic vaccine delivery systems provide consistent levels of gene expression and enhance efficiency of plasmid.
Not the Report you are looking for?Click here for more browsing options.
* If a currency is not selected, the report will be delivered in the local currency of the company ** Full access limits users to 500 reports per month
Web site and selected data copyright 2008 The Winthrop Corporation. All rights reserved. Selected data copyright 2008, "Worldscope/Disclosure, L.L.C., a Primark affiliate." All rights reserved.
